Genentech announces new data on CD20-CD3 T-cell in Hodgkin's lymphoma
Genentech, a member of the Roche Group, announced new data on two investigational CD20-CD3 T-cell engaging bispecific antibodies, mosunetuzumab and CD20-TCB, in people with relapsed or refractory B-cell non-Hodgkin's lymphoma. Results from the Phase I/Ib GO29781 study of mosunetuzumab, including data from people previously treated with chimeric antigen receptor T-cell therapy, will be presented at the 61st American Society of Hematology 2019 Annual Meeting. The GO29781 study evaluated mosunetuzumab in patients with R/R NHL, including patients who have relapsed following, or are resistant to, CAR T-cell therapy. Results from this dose-escalation study showed "encouraging efficacy" with an objective response rate of 62.7% in slow-growing NHL and 37.1% in aggressive NHL. Additionally, data demonstrated a complete response rate of 43.3% in slow-growing NHL and 19.4% in aggressive NHL. CRs showed durability, with 82.8% of patients with slow-growing NHL remaining in remission up to 26 months off initial treatment and 70.8% of patients with aggressive NHL, remaining in remission up to 16 months off initial treatment, the company added. Of the participants who received prior CAR T-cell therapy, the ORR was 38.9%, and 22.2% achieved a CR. Adverse reactions included cytokine release syndrome in 28.9% of patients with 20.0% at Grade 1 and 1.1% at Grade 3. Grade 3 neurological adverse events occurred in 3.7% of patients, Genentech said.